221 related articles for article (PubMed ID: 35910795)
1. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
[No Abstract] [Full Text] [Related]
2. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
3. IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy.
Hu B; Liu T; Li L; Shi L; Yao M; Li C; Ma X; Zhu H; Jia B; Wang F
Bioconjug Chem; 2022 Jul; 33(7):1328-1339. PubMed ID: 35687724
[TBL] [Abstract][Full Text] [Related]
4. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
[TBL] [Abstract][Full Text] [Related]
6. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
7. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe
Wu Y; Li L; Wang Z; Shi J; Hu Z; Gao S; Miao W; Ma Q; Dong C; Wang F
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2613-2623. PubMed ID: 32170344
[TBL] [Abstract][Full Text] [Related]
8. Development of
Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
[TBL] [Abstract][Full Text] [Related]
9. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
10. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of
Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V
Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776
[TBL] [Abstract][Full Text] [Related]
12. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
13. Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.
Ji S; Zheng Y; Shao G; Zhou Y; Liu S
Theranostics; 2013; 3(11):816-30. PubMed ID: 24312152
[TBL] [Abstract][Full Text] [Related]
14. Investigations of (99m)Tc-labeled glucarate as a SPECT radiotracer for non-small cell lung cancer (NSCLC) and potential tumor uptake mechanism.
Meng L; Xiu Y; Li Y; Xu X; Li S; Li X; Pak KY; Shi H; Cheng D
Nucl Med Biol; 2015 Jul; 42(7):608-13. PubMed ID: 25890861
[TBL] [Abstract][Full Text] [Related]
15. Integrin αvβ₆-Targeted SPECT Imaging for Pancreatic Cancer Detection.
Liu Z; Liu H; Ma T; Sun X; Shi J; Jia B; Sun Y; Zhan J; Zhang H; Zhu Z; Wang F
J Nucl Med; 2014 Jun; 55(6):989-94. PubMed ID: 24711651
[TBL] [Abstract][Full Text] [Related]
16. Direct In Vivo Comparison of
Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of [
Liu T; Wu Y; Shi L; Li L; Hu B; Wang Y; Gao H; Yu X; Zhang X; Zhao H; Wan Y; Jia B; Wang F
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1810-1821. PubMed ID: 35013776
[TBL] [Abstract][Full Text] [Related]
18. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
19. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Preliminary Study of
Ma M; Yang G; Zhao M; Liu Y; Ge X; Jia B; Gao S
Mol Pharm; 2024 Feb; 21(2):735-744. PubMed ID: 38193393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
